Business Wire

Westinghouse Signs Contract for Engineering of AP1000 ® Reactors in Bulgaria

Share

Westinghouse Electric Company, Hyundai Engineering & Construction Co. and Bulgaria’s Kozloduy NPP - New Build EAD today signed the Engineering Services Contract for two AP1000® reactors to be built at the Kozloduy site. Bulgarian Prime Minister Dimitar Glavchev, Bulgarian Minister of Energy Vladimir Malinov, U.S. Ambassador to Bulgaria Kenneth Merten, Executive Director of Kozloduy NPP - New Build Petyo Ivanov, Senior Vice President of Westinghouse Energy Systems Elias Gedeon, and Hyundai Engineering & Construction President and CEO Yoon Young-Joon attended the signing ceremony in Sofia.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104293861/en/

Following the signing ceremony. From left: Yoon Young-Joon, President and CEO, Hyundai Engineering & Construction; Ji I Cho, Deputy Head of Mission and Charge d'Affaires a.i., Embassy of the Republic of Korea; Vladimir Malinov, Minister of Energy, Bulgaria; Dimitar Glavchev, Prime Minister of Bulgaria; Elias Gedeon, Senior Vice President of Westinghouse Energy Systems; Kenneth Merten, U.S. Ambassador to Bulgaria; and Petyo Ivanov, Executive Director, Kozloduy NPP - New Build. (Photo: Business Wire)

The contract scope includes site planning for two Westinghouse AP1000® units, the most advanced Generation III+ nuclear reactor available today. In addition, the contract provides support for Kozloduy NPP - New Build EAD to begin licensing and permitting, while providing critical project planning and operations & maintenance development. The work outlined in the 12-month contract will begin immediately.

“Bulgaria has over 50 years of experience in the construction of nuclear facilities. And today's event will build on this experience and contribute to the independence, diversification and stability of nuclear energy in the country and throughout Europe. We are pleased to partner on the new build project with Westinghouse Electric Company and Hyundai Engineering & Construction, which are undisputed leaders in this field. I am convinced of the great success of the project, and the Bulgarian state will give its maximum for its successful implementation,” said Dimitar Glavchev, Bulgarian Prime Minister.

“The main priority of our cabinet is the development of nuclear energy. Our consistent efforts in this direction have led to today's event. We are thankful to Westinghouse Electric Company and Hyundai Engineering & Construction for responding to our request and forming a consortium. I believe that in less than 10 years we will have a working project that will be a guarantee for the Bulgarian population and country, that we will have clean energy at an affordable price,” said Vladimir Malinov, Bulgarian Minister of Energy.

“The United States fully supports Bulgaria’s efforts to ensure its energy security through the diversification of its energy sector. The construction of these two new reactors will both enhance Bulgaria’s energy security and position the country as a key energy hub for the region,” said Kenneth Merten, U.S. Ambassador to Bulgaria. “This project, using advanced American technology with unparalleled safety standards over years of safe operation, is poised to provide sustainable and secure energy for Bulgaria’s future.”

“We are pleased to extend our long-term relationship with Bulgaria, and to work closely in building two advanced AP1000 units that will bolster Bulgaria’s energy security,” said Dan Lipman, President of Westinghouse Energy Systems. “This project will not only deliver clean, safe and stable power to Bulgaria, it will also create high-quality jobs and real economic benefits for years to come and foster Bulgaria’s energy independence.”

Bulgaria’s first AP1000 nuclear reactor is anticipated to achieve commercial operation in 2035. Westinghouse has already signed Memoranda of Understanding with 22 Bulgarian suppliers to support the project. The two-unit Kozloduy project will also provide Bulgarian firms opportunities to support the more than 30 AP1000 units in the pipeline globally.

The AP1000 reactor is the only operating Generation III+ reactor with fully passive safety systems, modular construction design and the smallest footprint per MWe on the market. In China, there are four AP1000 reactors currently setting operational performance and availability records with eight additional reactors under construction and four more under contract. In addition, there are two operating AP1000 units at the Vogtle site in Georgia. The AP1000 technology has been selected for nuclear energy programs in Poland, Ukraine and Bulgaria, and is also under consideration at multiple other sites in Central and Eastern Europe, the United Kingdom, India and North America. There will be 18 units based on AP1000 technology in operation globally by the end of the decade.

Westinghouse Electric Company is shaping the future of carbon-free energy by providing safe, innovative nuclear and other clean power technologies and services globally. Westinghouse supplied the world’s first commercial pressurized water reactor in 1957 and the company’s technology is the basis for nearly one-half of the world's operating nuclear plants. Over 135 years of innovation makes Westinghouse the preferred partner for advanced technologies covering the complete nuclear energy life cycle. For more information, visit www.westinghousenuclear.com and follow us on Facebook, LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241104293861/en/

Contacts

media@westinghouse.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye